Khursheed Anwer - 04 Aug 2025 Form 4 Insider Report for Imunon, Inc. (IMNN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Aug 2025, 16:28:28 UTC
Prior SEC filing
18 Mar 2025
Next SEC filing
06 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Susan Eylward, Attorney-in-Fact for Khursheed Anwer
Filing notes and source

Key filing fact

Khursheed Anwer filed Form 4 for Imunon, Inc. (IMNN) on 06 Aug 2025.

Key facts

  • This page summarizes Khursheed Anwer's Form 4 filing for Imunon, Inc. (IMNN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 06 Aug 2025, 16:28.

Change

  • Previous filing in this sequence was filed on 18 Mar 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001611756 Primary reporting owner

Anwer Khursheed

Relationship
Chief Scientific Officer
Address
C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE
Signature
/s/ Susan Eylward, Attorney-in-Fact for Khursheed Anwer
Signature date
06 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+1,667
Change %
Price
$0.000000
Shares after
1,667
Date
04 Aug 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,667
Exercise price
$9.20
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

Footnote F2

The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC remarks

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .